TapewireFind a company

person · Reporting owner

Yanai Shlomo

Disclosed activity across 6 companies

Tapewire entity
10850
SEC CIK
0001562645

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Amneal Pharmaceuticals, Inc.AMRX · Entity 820DirectorMay 06, 2026May 08, 2026
PDL BIOPHARMA, INC.PDLI · Entity 143144DirectorJune 20, 2019June 25, 2019
Philip Morris International Inc.PM · Entity 2818DirectorMay 06, 2026May 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Amneal Pharmaceuticals, Inc.

Report date May 06, 2026 · Filed May 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect320,804 Reported balance After 2026-05-07 transaction · row 1
1 source row

Row 1 · 2026-05-07 · Exercise / conversion · Acquired 34,819 · Balance 320,804

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-05-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-07 · Exercise / conversion · Disposed 34,819 · Balance 0

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect19,824 Reported balance After 2026-05-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-05-06 · Grant · Acquired 19,824 · Balance 19,824

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

F3: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

PDL BIOPHARMA, INC.

Report date June 20, 2019 · Filed June 25, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2029-06-19Direct126,050 Reported balance After 2019-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-20 · Grant · Acquired 126,050 · Balance 126,050

F1: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date.

Philip Morris International Inc.

Report date May 06, 2026 · Filed May 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,120 Reported balance After 2026-05-06 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-06 · Grant · Acquired 1,119 · Balance 10,120

F1: Shares awarded under the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors.

F2: The average of the high and low price of Philip Morris International Inc. common stock on May 6, 2026.

F3: Includes 8,281 deferred shares held in the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors. This is an increase of 1,361 deferred shares, reflecting the total of the 2026 stock award and 242 deferred shares acquired through the reinvestment of dividends since May 7, 2025, the date of the last reportable transaction.

Filing footnotes · ownership attribution and instrument terms

F1: Shares awarded under the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors.

F2: The average of the high and low price of Philip Morris International Inc. common stock on May 6, 2026.

F3: Includes 8,281 deferred shares held in the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors. This is an increase of 1,361 deferred shares, reflecting the total of the 2026 stock award and 242 deferred shares acquired through the reinvestment of dividends since May 7, 2025, the date of the last reportable transaction.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CAMBREX CORP

Report date December 04, 2019 · Filed December 05, 2019

Section 16 reporting ended · disclosed 2019-12-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2019-12-04 transaction · row 8
8 source rows · reconciled sequence

Row 1 · 2019-12-04 · Exercise / conversion · Acquired 6,371 · Balance 21,857

Row 2 · 2019-12-04 · Exercise / conversion · Acquired 3,863 · Balance 25,720

Row 3 · 2019-12-04 · Exercise / conversion · Acquired 2,140 · Balance 27,860

Row 4 · 2019-12-04 · Exercise / conversion · Acquired 1,613 · Balance 29,473

Row 5 · 2019-12-04 · Exercise / conversion · Acquired 1,577 · Balance 31,050

Row 6 · 2019-12-04 · Exercise / conversion · Acquired 1,980 · Balance 33,030

Row 7 · 2019-12-04 · Exercise / conversion · Acquired 2,766 · Balance 35,796

Row 8 · 2019-12-04 · Sale · Disposed 35,796 · Balance 0

F1: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90Direct0 Reported balance After 2019-12-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2019-12-04 · Exercise / conversion · Acquired 6,371 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.70Direct0 Reported balance After 2019-12-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2019-12-04 · Exercise / conversion · Acquired 3,863 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.23Direct0 Reported balance After 2019-12-04 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2019-12-04 · Exercise / conversion · Acquired 2,140 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.12Direct0 Reported balance After 2019-12-04 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2019-12-04 · Exercise / conversion · Acquired 1,613 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.98Direct0 Reported balance After 2019-12-04 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2019-12-04 · Exercise / conversion · Acquired 1,577 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.70Direct0 Reported balance After 2019-12-04 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2019-12-04 · Exercise / conversion · Acquired 1,980 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Stock Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $40.06Direct0 Reported balance After 2019-12-04 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2019-12-04 · Exercise / conversion · Acquired 2,766 · Balance 0

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.

F2: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Exela Technologies, Inc.

Report date July 12, 2017 · Filed July 15, 2017

Section 16 reporting ended · disclosed 2017-07-15. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect20,500 Reported balance After 2017-07-12 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2017-07-12 · Disposition to issuer · Disposed 29,500 · Balance 20,500

F1: To facilitate a business combination involving the Issuer, SourceHOV Holdings, Inc. and Novitex Holdings Inc., which closed July 12, 2017 (the "Business Combination"), Mr. Yanai forfeited to the Issuer 29,500 shares of common stock. No consideration was received by Mr. Yanai for the disposition. Also in connection with the Business Combination, Mr. Yanai resigned his position as a director of the company effective the closing date, and as such, Mr. Yanai is no longer subject to the reporting obligations under Section 16 with respect to the Issuer.

F2: Mr. Yanai disclaims beneficial ownership in shares held by Quinpario Partners 2, LLC, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: To facilitate a business combination involving the Issuer, SourceHOV Holdings, Inc. and Novitex Holdings Inc., which closed July 12, 2017 (the "Business Combination"), Mr. Yanai forfeited to the Issuer 29,500 shares of common stock. No consideration was received by Mr. Yanai for the disposition. Also in connection with the Business Combination, Mr. Yanai resigned his position as a director of the company effective the closing date, and as such, Mr. Yanai is no longer subject to the reporting obligations under Section 16 with respect to the Issuer.

F2: Mr. Yanai disclaims beneficial ownership in shares held by Quinpario Partners 2, LLC, except to the extent of his pecuniary interest therein.

W R GRACE & CO

Report date September 22, 2021 · Filed September 22, 2021

Section 16 reporting ended · disclosed 2021-09-22. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivativeDirect0 Reported balance After 2021-09-22 transaction · row 1
1 source row

Row 1 · 2021-09-22 · Disposition to issuer · Disposed 6,973 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the Agreement & Plan of Merger (the "Merger Agreement"), dated April 26, 2021, among W. R. Grace & Co. ("Company"), W. R. Grace Holdings LLC (fka Gibraltar Acquisition Holdings LLC), a Delaware limited liability company ("Parent"), and Gibraltar Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on April 26, 2021, pursuant to which on Sept. 22, 2021, Merger Sub merged with and into the Company (the "Merger") and pursuant to which the Company survived the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each issued & outstanding share of Company common stock was cancelled and converted into the right to receive $70.00 in cash (the "Merger Consideration") without interest, subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the Agreement & Plan of Merger (the "Merger Agreement"), dated April 26, 2021, among W. R. Grace & Co. ("Company"), W. R. Grace Holdings LLC (fka Gibraltar Acquisition Holdings LLC), a Delaware limited liability company ("Parent"), and Gibraltar Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on April 26, 2021, pursuant to which on Sept. 22, 2021, Merger Sub merged with and into the Company (the "Merger") and pursuant to which the Company survived the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each issued & outstanding share of Company common stock was cancelled and converted into the right to receive $70.00 in cash (the "Merger Consideration") without interest, subject to withholding taxes.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 24, 2019 Filed Apr 25, 2019 20:35 UTC CAMBREX CORP CBM · Entity 153359 GrantCommon Stock 2,247 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-026063 · doc4.xml · nonDerivative · entry 1

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,486

Read SEC document
June 08, 2018 Filed Jun 12, 2018 20:29 UTC PDL BIOPHARMA, INC. PDLI · Entity 143144 GrantCommon stock 54,348 $2.76 $150,000.48
Disclosure

SEC source: 0000882104-18-000066 · wf-form4_152883534801960.xml · nonDerivative · entry 1

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,348

F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc.

Read SEC document
May 09, 2018 Filed May 11, 2018 16:25 UTC W R GRACE & CO GRA · Entity 135295 GrantCommon Stock, par value $0.01 per share 1,478 $0.00 $0.00
Disclosure

SEC source: 0001045309-18-000079 · wf-form4_152607029912157.xml · nonDerivative · entry 1

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,478

F1 · price: Issued in partial payment for 2018 retainer.

Read SEC document
April 26, 2018 Filed Apr 30, 2018 20:49 UTC CAMBREX CORP CBM · Entity 153359 GrantStock Option (right to buy) · Derivative 1,980 $0.00 Strike: $53.70 $0.00
Disclosure

SEC source: 0001209191-18-026948 · doc4.xml · derivative · entry 2

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,980

Underlying: Common Stock · 1,980 shares

Expires 2025-04-25

Read SEC document
April 26, 2018 Filed Apr 30, 2018 20:49 UTC CAMBREX CORP CBM · Entity 153359 GrantCommon Stock 1,397 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-026948 · doc4.xml · nonDerivative · entry 1

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,239

Read SEC document
July 12, 2017 Filed Jul 15, 2017 01:16 UTC Exela Technologies, Inc. XELA · Entity 76832 Disposition to issuerCommon Stock 29,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-17-045127 · a4.xml · nonDerivative · entry 1

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

F1 · price: To facilitate a business combination involving the Issuer, SourceHOV Holdings, Inc. and Novitex Holdings Inc., which closed July 12, 2017 (the "Business Combination"), Mr. Yanai forfeited to the Issuer 29,500 shares of common stock. No consideration was received by Mr. Yanai for the disposition. Also in connection with the Business Combination, Mr. Yanai resigned his position as a director of the company effective the closing date, and as such, Mr. Yanai is no longer subject to the reporting obligations under Section 16 with respect to the Issuer.

F2 · ownership.direct: Mr. Yanai disclaims beneficial ownership in shares held by Quinpario Partners 2, LLC, except to the extent of his pecuniary interest therein.

Read SEC document
April 27, 2017 Filed May 1, 2017 16:18 UTC CAMBREX CORP CBM · Entity 153359 GrantStock Option (right to buy) · Derivative 1,577 $0.00 Strike: $58.98 $0.00
Disclosure

SEC source: 0001437749-17-007613 · rdgdoc.xml · derivative · entry 2

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,577

Underlying: Common Stock · 1,577 shares

Expires 2024-04-26

Read SEC document
April 27, 2017 Filed May 1, 2017 16:18 UTC CAMBREX CORP CBM · Entity 153359 GrantCommon Stock 1,187 $0.00 $0.00
Disclosure

SEC source: 0001437749-17-007613 · rdgdoc.xml · nonDerivative · entry 1

Yanai Shlomo · CIK 0001562645 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,842

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.